Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Positive Metastatic Breast Cancers”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00303992
What this trial is testing

Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
University of California, San Francisco 9
Testing effectiveness (Phase 2)WithdrawnNCT02853071
What this trial is testing

Efficacy and Safety of Estracyt® in Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Centre Hospitalier Universitaire de Besancon
Testing effectiveness (Phase 2)UnknownNCT04639271
What this trial is testing

Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis

Who this might be right for
Breast CancerHER2-positive Breast Cancer
Shandong Cancer Hospital and Institute 100
Early research (Phase 1)Study completedNCT02152943
What this trial is testing

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

Who this might be right for
Advanced Malignant Solid NeoplasmEstrogen Receptor PositiveHER2/Neu Positive+10 more
M.D. Anderson Cancer Center 37
Large-scale testing (Phase 3)Active Not RecruitingNCT05424835
What this trial is testing

A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

Who this might be right for
HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Jiangsu HengRui Medicine Co., Ltd. 381
Large-scale testing (Phase 3)Active Not RecruitingNCT05909397
What this trial is testing

Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer

Who this might be right for
Breast Cancer
Pfizer 59
Testing effectiveness (Phase 2)Looking for participantsNCT07258108
What this trial is testing

Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors

Who this might be right for
Breast Cancer
Sun Yat-sen University 35
Testing effectiveness (Phase 2)Study completedNCT02344550
What this trial is testing

Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Asan Medical Center 137
Testing effectiveness (Phase 2)Looking for participantsNCT05524584
What this trial is testing

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast CancerHormone Receptor-positive Breast Cancer+1 more
University of California, Irvine 20
Testing effectiveness (Phase 2)Ended earlyNCT00079326
What this trial is testing

Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast CancerRecurrent Breast CancerStage IV Breast Cancer
National Cancer Institute (NCI) 39
Testing effectiveness (Phase 2)Study completedNCT02362958
What this trial is testing

A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer

Who this might be right for
HER2 Positive Breast Cancer
Sun Yat-sen University 159
Early research (Phase 1)Study completedNCT00911898
What this trial is testing

MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers

Who this might be right for
Her2 Amplified Solid TumorsMetastatic Breast Cancer
Merrimack Pharmaceuticals 20
Testing effectiveness (Phase 2)Study completedNCT01242449
What this trial is testing

Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Vejle Hospital 10
Large-scale testing (Phase 3)Not Yet RecruitingNCT07802626
What this trial is testing

Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing

Who this might be right for
HR Positive/HER-2 Negative Breast Cancer
SWOG Cancer Research Network 1,084
Testing effectiveness (Phase 2)Looking for participantsNCT05748834
What this trial is testing

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Who this might be right for
Breast Cancer
SCRI Development Innovations, LLC 36
Early research (Phase 1)Study completedNCT01602406
What this trial is testing

Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer

Who this might be right for
Advanced HER2-positive Breast Cancer or Gastric Cancer
Novartis Pharmaceuticals 64
Large-scale testing (Phase 3)Study completedNCT02896855
What this trial is testing

Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 243
Large-scale testing (Phase 3)UnknownNCT03966898
What this trial is testing

SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 426
Large-scale testing (Phase 3)Active Not RecruitingNCT04895358
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Who this might be right for
Breast Neoplasms
Merck Sharp & Dohme LLC 342
Testing effectiveness (Phase 2)Looking for participantsNCT06298084
What this trial is testing

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd

Who this might be right for
Breast Cancer MetastaticHER2-positive Metastatic Breast CancerHER2 Low Breast Carcinoma+1 more
Gustave Roussy, Cancer Campus, Grand Paris 152
Next Page